Literature DB >> 25378088

Novel strategies and underlying protective mechanisms of modulation of vagal activity in cardiovascular diseases.

Xi He1, Ming Zhao1, Xueyuan Bi1, Lei Sun1, Xiaojiang Yu1, Mei Zhao1, Weijin Zang1.   

Abstract

Cardiovascular disease remains a major cause of disability and death worldwide. Autonomic imbalance, characterized by suppressed vagal (parasympathetic) activity and increased sympathetic activity, correlates with various pathological conditions, including heart failure, arrhythmia, ischaemia/reperfusion injury and hypertension. Conventionally, pharmacological interventions, such as β-blocker treatment, have primarily targeted suppressing sympathetic over-activation, while vagal modulation has always been neglected. Emerging evidence has documented the improvement of cardiac and vascular function mediated by the vagal nerve. Many investigators have tried to explore the effective ways to enhance vagal tone and normalize the autonomic nervous system. In this review, we attempt to give an overview of these therapeutic strategies, including direct vagal activation (electrical vagal stimulation, ACh administration and ACh receptor activation), pharmacological modulation (adenosine, cholinesterase inhibitors, statins) and exercise training. This overview provides valuable information for combination therapy, contributing to establishment of a comprehensive system on vagal modulation from the aspects of clinical application and lifestyle improvement. In addition, the mechanisms contributing to the benefits of enhancing vagal tone are diverse and have not yet been fully defined. We endeavour to outline the recent findings that advance our knowledge regarding the many favourable effects exerted by vagal activation: anti-inflammatory pathways, modulation of NOS and NO signalling, regulation of redox state, improvement of mitochondrial biogenesis and function, and potential calcium regulation. This review may help to develop novel therapeutic strategies targeting enhancing vagal activity for the treatment of cardiovascular diseases.
© 2014 The British Pharmacological Society.

Entities:  

Mesh:

Year:  2015        PMID: 25378088      PMCID: PMC4667861          DOI: 10.1111/bph.13010

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  111 in total

1.  Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure.

Authors:  Bojan Vrtovec; Renata Okrajsek; Alenka Golicnik; Mateja Ferjan; Vito Starc; Branislav Radovancevic
Journal:  J Card Fail       Date:  2005-12       Impact factor: 5.712

Review 2.  Mitochondria in vascular health and disease.

Authors:  Peter Dromparis; Evangelos D Michelakis
Journal:  Annu Rev Physiol       Date:  2012-11-16       Impact factor: 19.318

3.  α7 nicotinic acetylcholine receptor signaling inhibits inflammasome activation by preventing mitochondrial DNA release.

Authors:  Ben Lu; Kevin Kwan; Yaakov A Levine; Peder S Olofsson; Huan Yang; Jianhua Li; Sonia Joshi; Haichao Wang; Ulf Andersson; Sangeeta S Chavan; Kevin J Tracey
Journal:  Mol Med       Date:  2014-08-14       Impact factor: 6.354

Review 4.  Muscarinic acetylcholine receptors: novel opportunities for drug development.

Authors:  Andrew C Kruse; Brian K Kobilka; Dinesh Gautam; Patrick M Sexton; Arthur Christopoulos; Jürgen Wess
Journal:  Nat Rev Drug Discov       Date:  2014-06-06       Impact factor: 84.694

Review 5.  Endothelial nicotinic acetylcholine receptors and angiogenesis.

Authors:  John P Cooke; Yohannes T Ghebremariam
Journal:  Trends Cardiovasc Med       Date:  2008-10       Impact factor: 6.677

6.  Acetylcholine attenuates hypoxia/ reoxygenation-induced mitochondrial and cytosolic ROS formation in H9c2 cells via M2 acetylcholine receptor.

Authors:  Yi Miao; Jun Zhou; Mei Zhao; Jinjun Liu; Lei Sun; Xiaojiang Yu; Xi He; Xiaoyue Pan; Weijin Zang
Journal:  Cell Physiol Biochem       Date:  2013-02-08

7.  Pyridostigmine prevents peripheral vascular endothelial dysfunction in rats with myocardial infarction.

Authors:  Fangfang Qin; Yi Lu; Xi He; Ming Zhao; Xueyuan Bi; Xiaojiang Yu; Jinjun Liu; Weijin Zang
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-03       Impact factor: 2.557

8.  The Concise Guide to PHARMACOLOGY 2013/14: enzymes.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

9.  Vagal nerve stimulation protects cardiac injury by attenuating mitochondrial dysfunction in a murine burn injury model.

Authors:  Xiaojiong Lu; Todd Costantini; Nicole E Lopez; Paul L Wolf; Ann-Marie Hageny; James Putnam; Brian Eliceiri; Raul Coimbra
Journal:  J Cell Mol Med       Date:  2013-04-12       Impact factor: 5.310

Review 10.  Mitochondria, endothelial cell function, and vascular diseases.

Authors:  Xiaoqiang Tang; Yu-Xuan Luo; Hou-Zao Chen; De-Pei Liu
Journal:  Front Physiol       Date:  2014-05-06       Impact factor: 4.566

View more
  20 in total

Review 1.  Autonomic dysfunction in programmed hypertension.

Authors:  Hasthi U Dissanayake; Michael R Skilton; Jaimie W Polson
Journal:  J Hum Hypertens       Date:  2018-12-05       Impact factor: 3.012

Review 2.  Advances in understanding mechanisms and therapeutic targets to treat comorbid depression and cardiovascular disease.

Authors:  Brittany S Pope; Susan K Wood
Journal:  Neurosci Biobehav Rev       Date:  2020-06-26       Impact factor: 8.989

3.  Cocaine cardiovascular effects and pharmacokinetics after treatment with the acetylcholinesterase inhibitor donepezil.

Authors:  Kenneth Grasing; Deepan Mathur; Cherilyn DeSouza; Thomas F Newton; David E Moody; Marc Sturgill
Journal:  Am J Addict       Date:  2016-07-08

4.  Acetylcholine ameliorates endoplasmic reticulum stress in endothelial cells after hypoxia/reoxygenation via M3 AChR-AMPK signaling.

Authors:  Xueyuan Bi; Xi He; Man Xu; Ming Zhao; Xiaojiang Yu; Xingzhu Lu; Weijin Zang
Journal:  Cell Cycle       Date:  2015-06-11       Impact factor: 4.534

5.  Amelioration of circadian disruption and calcium-handling protein defects by choline alleviates cardiac remodeling in abdominal aorta coarctation rats.

Authors:  Xi He; Si Yang; Juan Deng; Qing Wu; Wei-Jin Zang
Journal:  Lab Invest       Date:  2021-03-01       Impact factor: 5.662

6.  Using the Oculocardiac Reflex to Characterize Autonomic Imbalance in a Naturally Occurring Canine Model of Valvular Insufficiency.

Authors:  Bruna C Brüler; Thayane C Vieira; Marcela Wolf; Stephany B Lucina; Fabiano Montiani-Ferreira; Marlos G Sousa
Journal:  Comp Med       Date:  2018-04-02       Impact factor: 0.982

7.  Inhibition of the mitochondrial unfolded protein response by acetylcholine alleviated hypoxia/reoxygenation-induced apoptosis of endothelial cells.

Authors:  Man Xu; Xueyuan Bi; Xi He; Xiaojiang Yu; Ming Zhao; Weijin Zang
Journal:  Cell Cycle       Date:  2016-04-25       Impact factor: 4.534

8.  Potential neurobiological benefits of exercise in chronic pain and posttraumatic stress disorder: Pilot study.

Authors:  Erica Scioli-Salter; Daniel E Forman; John D Otis; Carlos Tun; Kelly Allsup; Christine E Marx; Richard L Hauger; Jillian C Shipherd; Diana Higgins; Anna Tyzik; Ann M Rasmusson
Journal:  J Rehabil Res Dev       Date:  2016

Review 9.  Muscarinic Stimulation Facilitates Sarcoplasmic Reticulum Ca Release by Modulating Ryanodine Receptor 2 Phosphorylation Through Protein Kinase G and Ca/Calmodulin-Dependent Protein Kinase II.

Authors:  Hsiang-Ting Ho; Andriy E Belevych; Bin Liu; Ingrid M Bonilla; Przemysław B Radwański; Igor V Kubasov; Héctor H Valdivia; Karsten Schober; Cynthia A Carnes; Sándor Györke
Journal:  Hypertension       Date:  2016-09-19       Impact factor: 10.190

10.  Chinese innovation in cardiovascular drug discovery.

Authors:  Xin Wang; Yong Ji; Baofeng Yang
Journal:  Br J Pharmacol       Date:  2015-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.